MS is a progressive, chronic inflammatory, and neurodegenerative disease of the central nervous system, that can take a heavy toll on the lives of those affected. MS cannot be cured, but treatments can modify the course of disease. Due to the high costs of medication, broader access to more affordable treatment options is needed to reduce the substantial economic impact of MS on healthcare systems – which is estimated to be as much €37,000-€57,000 per patient per year, in both direct and indirect costs for those with moderate-to-severe disease.
EU marketing authorization through the centralized procedure is valid in all EU Member States, as well as the European Economic Area countries Iceland, Liechtenstein, Norway, and Northern Ireland under the Northern Ireland Protocol. Outside Europe, Tyruko was approved by the U.S. Food and Drug Administration (FDA) in August 2023. For Great Britain, approval is pending.
Digital issue: Please click here for more information